Prolastin c 1,000 MG/20 ML VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FMEG8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,922
Award facts
- Contract value 100% obligated
- $17,922.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,922.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of February 19, 2026, and no set-aside designation was applied. This award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for pharmaceutical supply to Department of Defense healthcare operations worldwide. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036.
DMS Pharmaceutical Group Inc. has demonstrated consistent performance as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the DLA's Medical Supply Chain division. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables serving military healthcare facilities globally. No subcontractors were identified for this award, with DMS Pharmaceutical Group performing as the sole prime contractor responsible for fulfilling all delivery obligations.
Quick answers
Who was awarded contract SPE2DR26FMEG8?
SPE2DR26FMEG8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FMEG8 worth?
The government has obligated $17,922 on SPE2DR26FMEG8.
Is contract SPE2DR26FMEG8 an order under another contract?
Yes. SPE2DR26FMEG8 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEG8 competed?
The extent of competition for SPE2DR26FMEG8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award